Kenvue Inc. Reports Strong Q1 Performance, Boosts Sales Outlook

Kenvue Inc., a leading consumer health company known for brands like Neutrogena, Listerine, and Tylenol, has reported a robust first-quarter performance in 2025, surpassing profit forecasts and revising its sales outlook upwards. The company, which operates in self-care, skin health & beauty, and essential health products, serves customers globally and is listed on the New York Stock Exchange.

On May 8, 2025, multiple financial news sources highlighted Kenvue’s impressive earnings results. According to reports from Benzinga and Investing.com, Kenvue exceeded earnings estimates and lifted its sales outlook. The company’s Q1 earnings call transcript, as covered by Seeking Alpha, provided further insights into its financial performance.

Despite an organic sales decline attributed to strategic investments, Kenvue maintained its outlook, as noted by Investing.com. The company’s adjusted earnings are now expected to be at the low end of the prior forecast range, as reported by Finanznachrichten.de. This adjustment comes alongside the appointment of Amit Banati as the new CFO, succeeding Paul Ruh.

Kenvue’s strength in its self-care unit was a significant contributor to its Q1 results, which beat estimates, as reported by Investing.com. The company’s Q2 earnings and revenue also surpassed expectations, reinforcing its positive trajectory.

The company’s market capitalization stands at $45.97 billion, with a close price of $23.57 as of May 5, 2025. Kenvue’s price-to-earnings ratio is 44.76, reflecting investor confidence in its growth potential. The company’s 52-week high was $24.46, reached on November 25, 2024, while its low was $17.67 on July 10, 2024.

Overall, Kenvue’s upbeat Q1 earnings and revised sales outlook signal a strong start to the year, despite some challenges in organic sales growth. The company’s strategic investments and leadership changes position it well for continued success in the consumer staples sector.